We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+7.34%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$314M
AUM Growth
-$11.8M
Cap. Flow
+$118M
Cap. Flow %
37.6%
Top 10 Hldgs %
75.78%
Holding
42
New
10
Increased
6
Reduced
8
Closed
11
Avg Time Held Equity + Options
2 quarters
Top 10 Avg Time Held Equity + Options
2.1 quarters
Top 20 Avg Time Held Equity + Options
1.7 quarters
Avg Time Held Equity only
2 quarters
Top 10 Avg Time Held Equity only
2.5 quarters
Top 20 Avg Time Held Equity only
2.2 quarters

Top Buys

Rank Stock Value
1
FAST icon
Fastenal
FAST
+$111M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$19.8M
3
ASND icon
Ascendis Pharma A/S
ASND
+$15.1M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$10.6M
5
EDIT icon
Editas Medicine
EDIT
+$9.51M

Top Sells

Rank Stock Value
1
DERM icon
Dermira, Inc.
DERM
+$15.4M
2
KA icon
Kineta, Inc. Common Stock
KA
+$9.39M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$9.27M
4
CYTK icon
Cytokinetics
CYTK
+$8.4M
5
AKAO
Achaogen Inc
AKAO
+$8.05M

Sector Composition

Rank Sector Weight
1 Healthcare 88.06%
2 Miscellaneous 9.92%
3 Industrials 2.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$593M
$43.7M 13.9%
3,409,485
+53,969
+2% +$682K
2015 Q4
4 quarters
LKFT icon
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$36M 11.47%
561,341
+60,765
+12% +$3.74M
2015 Q4
4 quarters
ASMB icon
3
Assembly Biosciences
ASMB
$414M
$35.8M 11.38%
245,264
– –
2014 Q4
8 quarters
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$19.8M 6.32%
+162,200
New +$19.8M
2016 Q4
0 quarters
ASND icon
5
Ascendis Pharma A/S
ASND
$14.7B
$19.7M 6.29%
975,700
+756,500
+345% +$15.1M
2016 Q3
1 quarter
ARDX icon
6
Ardelyx
ARDX
$806M
$18.6M 5.92%
1,310,023
– –
2016 Q3
1 quarter
KURA icon
7
Kura Oncology
KURA
$874M
$15.4M 4.91%
2,611,906
– –
2015 Q4
4 quarters
FPRX
8
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$15M 4.77%
298,712
+12,100
+4% +$636K
2016 Q3
1 quarter
KYNB icon
9
Kyntra Bio
KYNB
$23.8M
$14.7M 4.67%
27,447
– –
2014 Q4
8 quarters
ACRS icon
10
Aclaris Therapeutics
ACRS
$511M
$11.2M 3.58%
+414,000
New +$10.6M
2016 Q4
0 quarters
AGN
11
CALL
DELISTED
Allergan plc
AGN
$10.5M 3.34%
50,000
– –
2016 Q2
2 quarters
EDIT icon
12
Editas Medicine
EDIT
$375M
$10.2M 3.24%
+626,762
New +$9.51M
2016 Q4
0 quarters
XNCR icon
13
Xencor
XNCR
$1.75B
$9.87M 3.14%
+375,000
New +$9.02M
2016 Q4
0 quarters
CMRX icon
14
DELISTED
Chimerix, Inc.
CMRX
$6.51M 2.07%
1,415,687
+817,625
+137% +$3.86M
2016 Q3
1 quarter
FAST icon
15
Fastenal
FAST
$59B
$6.37M 2.03%
+10,148,104
New +$111M
2016 Q4
0 quarters
ATRA icon
16
Atara Biotherapeutics
ATRA
$93.4M
$3.06M 0.98%
+8,632
New +$3.65M
2016 Q4
0 quarters
ADVM icon
17
DELISTED
Adverum Biotechnologies
ADVM
$2.54M 0.81%
87,445
-7,181
-8% -$235K
2016 Q3
1 quarter
KIN
18
DELISTED
Kindred Biosciences, Inc.
KIN
$2.43M 0.77%
571,126
-861,639
-60% -$4.17M
2014 Q4
8 quarters
ATYR icon
19
aTyr Pharma
ATYR
$19.7M
$2.1M 0.67%
+69,785
New +$2.86M
2016 Q4
0 quarters
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.25B
$1.96M 0.63%
273,862
-83,503
-23% -$915K
2016 Q1
3 quarters
EGLT
21
DELISTED
Egalet Corporation
EGLT
$1.7M 0.54%
+222,300
New +$1.63M
2016 Q4
0 quarters
NBRV
22
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.58M 0.5%
1,059
-1,137
-52% -$1.51M
2015 Q3
5 quarters
DERM icon
23
DELISTED
Dermira, Inc.
DERM
$1.31M 0.42%
43,200
-478,800
-92% -$15.4M
2016 Q2
2 quarters
AGIO icon
24
Agios Pharmaceuticals
AGIO
$1.8B
$972K 0.31%
23,300
-176,700
-88% -$9.27M
2016 Q3
1 quarter
SYRS icon
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$773K 0.25%
6,360
– –
2016 Q3
1 quarter
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2016 Portfolio in Review

As of Q4 2016, EcoR1 Capital held 42 positions worth $314M, down 3.6% from $326M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

EcoR1 Capital deployed $118M of net new capital in Q4 2016, opening 10 new positions and adding to 6 existing holdings. Its largest new stake was Fastenal: 10,148,104 shares worth $6.37M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 80% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Dermira, Inc., an estimated $15.4M trimmed.

  • EcoR1 Capital's largest Q4 2016 buy was Fastenal: 10,148,104 shares worth $6.37M.
  • EcoR1 Capital added most to Ascendis Pharma A/S in Q4 2016, an estimated $15.1M increase.
  • EcoR1 Capital's biggest Q4 2016 reduction was Dermira, Inc., cutting an estimated $15.4M.
  • EcoR1 Capital fully exited Kineta, Inc. Common Stock in Q4 2016, selling an estimated $9.39M.
  • EcoR1 Capital's ten largest holdings make up 76% of its $314M portfolio in Q4 2016.
  • EcoR1 Capital opened 10 new positions and closed 11 in Q4 2016.
  • EcoR1 Capital's portfolio value fell 3.6% quarter-over-quarter to $314M.

Based on EcoR1 Capital's 13F filing for Q4 2016, filed 14 Feb 2017.